BSEResult4 Nov 2026 · 4 Nov 2026, 12:08 am

Intimation of the Integrated Unaudited Financial Results for the quarter and half year ended September 30, 2026.

Evonile Pharma Ltd · 500672

✦ AI SummaryResults

Evonile Pharma Ltd has submitted a revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, to rectify an inadvertent omission in the heading of a table under 'Disclosure of Outstanding Default on Loans and Debt Securities'. The figures disclosed in the table were correctly stated, but the expression '(INR in crores)' was omitted from the column heading. The amount disclosed against 'Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions' should be read as ₹800 crores as on September 30, 2026.

Analysis Scores

Earnings Impact5/10
Growth Catalyst2/10
Governance Concern1/10
Regulatory Risk1/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10

✦ Ask a Question

Ask anything about this announcement — AI will answer based on the filing content.

0/500

Full Announcement

Evonile Pharma Ltd - 500672 - Intimation Of The Integrated Unaudited Financial Results For The Quarter And Half Year Ended September 30, 2026.

Attachments (1)

📄

21d91efe-8d62-4535-89ee-ff48cd72c236.pdf

pdf

Download →
View document text
Evonile Pharma Limited (formerly known as Novartis India Limited) November 03, 2026 The Secretary, BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001. Scrip Code: 500672 Sub.: Integrated Filing (Financial) for the Quarter and half year ended September 30, 2026. Dear Sir/ Madam, Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, we hereby submit the revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, comprising the Unaudited Financial Statements together with the Limited Review Report thereon (Annexures I and II) and other disclosures forming part of the said filing. This revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table appearing under "Disclosure of Outstanding Default on Loans and Debt Securities" on page 2 of the disclosure submitted earlier on November 03, 2026, at 7:23 p.m. While the figures disclosed in the table were correctly stated, the expression "(INR in crores)" was inadvertently omitted from the column heading. Accordingly, it is clarified that the amount disclosed against "A. Total amount outstanding as on date" under "Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions" should be read as ₹800 crores as on September 30, 2026. Further, the amount disclosed against "Total financial indebtedness of the listed entity including short-term and long-term debt" should also be read as ₹800 crores. We confirm that all other disclosures and particulars contained in the earlier submission remain unchanged. There is no change whatsoever in the Unaudited Financial Results, Limited Review Report, Related Party Transactions disclosure, or any other information forming part of the Integrated Filing (Financial). This revised filing is being made solely to correct the aforesaid omission in the table heading. Kindly take the same on record. For Evonile Pharma Limited (Formerly known as Novartis India Limited) Chandni Maru Company Secretary & Compliance Officer A60291 Encl: as above Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Integrated Filing (Financial) for the quarter and half year ended September 30, 2026. B. Statement on Deviation or Variation for Proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement etc.: Not Applicable C. Disclosure of Outstanding Default on Loans and Debt Securities: - Not Applicable Sr Particulars Amount No. (INR in Crores) 1. Loans / revolving facilities like cash credit from banks / financial institutions A. Total amount outstanding as on date 800 B. Of the total amount outstanding, amount of default as on Nil date 2. Unlisted debt securities i.e. NCDs and NCRPS - A. Total amount outstanding as on date - B. Of the total amount outstanding, amount of default as on - date 3. Total financial indebtedness of the listed entity including 800 short-term and long-term debt D. Disclosure of Related Party Transactions (Applicable only for Half Yearly Filings (i.e. 02nd and 04th Quarter): Annexure-III E. Statement on Impact of Audit Qualifications (For Audit Report with Modified Opinion) Submitted Along with Annual Audited Financial Results (Standalone and Consolidated Separately) (Applicable Only for Annual Filing i.e. 4th Quarter): Not Applicable Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Annexure III Value of the related Value Value party Value of of of transac transacti transac transac Type of tion as on tion tion In case amount related approv during during during are due to either Details of the counterparty party ed by the the the party as a result transacti the reportin reporti reporti of the transaction on audit g period ng ng Sr. commit QTD period period No tee/ Sep'26 YTD YTD Board Sep'26 Jun'26 FY26 Relationship of the Openi counterpart Name Name y with the QTD YTD YTD ng Closing Sep'26 Sep'26 Jun'26 balan balance listed entity or its subsidiary Novartis Subsidiary Royalty - AG - Upto 48.76 1.43 9.42 7.99 10.92 -8.48 29th July 2026 Novartis Subsidiary NBS -2.23 Healthcare services 30.00 1.97 7.90 5.92 -2.23 Private Limited - Upto 29th July 2026 Novartis Subsidiary Business Healthcare support 66.00 20.06 34.67 14.61 -3.05 -25.51 Private services 3 Evonile Limited - availed Pharma Upto 29th Limited July 2026 (Formely known as Novartis Subsidiary Promotio Novartis Healthcare nal and 12.10 0.74 2.86 2.13 0.81 0.79 4 India Private marketin Lim ited) Limited - g Upto 29th services July 2026 Novartis Subsidiary ESO Healthcare services 41.00 0.42 6.97 6.55 3.05 0.45 Private provided Limited - Upto 29th July 2026 Subsidiary Employe Novartis Healthcare e 5.00 0.35 0.35 - - -0.24 6 balances Private transferr Limited - Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com Evonile Pharma Limited (formerly known as Novartis India Limited) Upto 29th ed – July 2026 payable Subsidiary Employe 0.00 Novartis e 5.00 2.85 2.85 - - Healthcare balances Private 7 transferr Limited - ed – Upto 29th receivabl July 2026 Novartis Subsidiary Providen India t fund 120.00 0.47 2.18 1.70 - - Limited contributi Employees' on Provident Fund Novartis Subsidiary Superann India uation 3.00 - - - - - 9 Limited contributi Superannu on ation Fund Novartis Subsidiary Gratuity 0.00 India fund 23.00 - - - - 10 Limited contributi Gratuity on fund Novartis Subsidiary Purchase - Pharma of stock 3,000. 97.80 526.57 428.77 293.3 -97.80 11 AG - Upto in trade 00 2 29th July 2026 Novartis- Subsidiary ESOP / Mitarbeiter ESPP 10.00 - 0.06 0.06 -3.50 - beteiligung 12 sstiftung (MBS) - Upto 29th July 2026 Tot 3363.86 126.09 593.83 467.74 Registered Office: Inspire BKC, 7th Floor, Bandra-Kurla Complex, Bandra (East), Mumbai - 400051, Maharashtra, India. CIN: L24200MH1947PLC006104 | Tel: +91 22 50243000 Email: investor.relations@evonilepharma.com | Website: www.evonilepharma.com